Clinical Trial Update: Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating VX-210 for acute traumatic cervical spinal cord injury was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Spinal Cord Injury

Drugs mentioned

• VX-210

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cervical Spinal Cord Injury | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2020-01-22